The Danish drugmaker released a promising update about a trial in China, but that didn’t end a rough run for shares.
A key investor said in an SEC filing that it may soon take action to boost shares.
GAAP, but GAAP profits lag as SBC weighs. Amid a correction in software stocks, the stock hasn't fallen enough to attract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results